Incidence of skin cancer in Japanese psoriatic patients treated with either methoxsalen phototherapy, Goeckerman regimen, or both therapies

Torinuki, Wakio; Tagami, Hachiro

doi:10.1016/s0190-9622(88)70135-8

Cited by 46 publications

(17 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most of the other retrospective European studies published before 1990 did not find any influence of PUVA treatment on the risk of skin cancer 28,30–37 . By contrast, more recent studies, with longer follow‐up were nearly all unanimous about the independent skin carcinogenic risk linked to PUVA 40–44 …”

Section: Resultsmentioning

confidence: 99%

“…Most of the other retrospective European studies published before 1990 did not find any influence of PUVA treatment on the risk of skin cancer. 28,[30][31][32][33][34][35][36][37] By contrast, more recent studies, with longer follow-up were nearly all unanimous about the independent skin carcinogenic risk linked to PUVA. [40][41][42][43][44] Similarly, most of the pre-1990 retrospective US studies [28][29][30]32 failed to find a link between exposure to PUVA and skin cancer.…”

Section: Risk Of Skin Cancer With Puva In Patients With Psoriasismentioning

confidence: 99%

See 1 more Smart Citation

Carcinogenic risks of Psoralen UV‐A therapy and Narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review

Archier

Devaux

Castela³

et al. 2012

Acad Dermatol Venereol

270

185

View full text Add to dashboard Cite

There is an increased risk of skin cancer following PUVA, shown by both US and European studies. The greater risk measured by the US studies may be at least partly explained by high UVA dose exposure and the lighter phototypes of the treated patients. The lack of prospective studies in psoriasis patients treated with NB-UVB constitutes a barrier to the robust assessment of carcinogenic risk of this phototherapy technique.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Risk Of Skin Cancer With Puva In Patients With Psoriasismentioning

confidence: 99%

Carcinogenic risks of Psoralen UV‐A therapy and Narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review

Archier

Devaux

Castela³

et al. 2012

Acad Dermatol Venereol

270

185

View full text Add to dashboard Cite

show abstract

“…However, if one understands the critical details involved in this report, it is easy to appreciate that, even if this report is valid, the implications may not apply to elderly patients or patients who are of ethnic backgrounds other than Caucasian since the major findings were based on a practically all-Caucasian population, for whom the risk was alledged to have increased in those who had at least 250 PUVA treatment sessions. According to the published scientific literature, it is not clear whether PUVA phototherapy increases the skin cancer risk of any type in non-Caucasians; the available long-term follow-up data from non-Caucasian populations show negative findings even for squamous cell carcinoma of the skin (10,11). Moreover, the alleged findings were not evident until at least 15 years into the follow-up observation period.…”

Section: Optimizing the Aggressiveness Of An Anti-psoriatic Regimenmentioning

confidence: 99%

Current Consensus and Update on Psoriasis Therapy: A Perspective from the U.S.

Koo

1999

The Journal of Dermatology

View full text Add to dashboard Cite

Psoriasis is one of the more common forms of chronic dermatitis in the world. The latest U.S.-wide epidemiological study conducted by the author revealed a prevalence rate of 2.6% of the population, which translates to over 6 million Americans (1). Psoriasis comes in many different degrees of severity and responsiveness to treatment modalities. Some cases are very mild and quite responsive to treatment, while others are so severe, chronic and recalcitrant that they test the skill and ingenuity of the best clinicians. Fortunately, there are also many different treatment options. Topical therapies include crude coal tar, anthralin, corticosteroids, calcipotriol, and tazarotene. Phototherapy may be a better choice in patients with more extensive psoriasis; UVB or psoralen plus subsequest UVA (PUVA) can be used. There are also a host of systemic therapies (cyclosporine, methotrexate, acitretin), which can be chosen in recalcitrant cases, or when topical or phototherapy is impractical. Importantly, significant increases in efficacy can be obtained by combining multiple therapies (Re-PUVA, topical calcipotriol plus topical halobetasol) and significant decreases in side effects can be obtained by transitioning through or rotating between therapies (cyclosporine transitioning into acitretin).

show abstract

“…As yet, the potential long-term risk of carcinogenesis of 5-MOP-UVA therapy has not been assessed: on the other hand, a few investigations of nonmelanoma skin cancers occurring in large groups of patients treated with 8-MOP-UVA therapy for long periods have reported contrasting results, perhaps because of different treatment schedules (12)(13)(14)(15)(16)(17). The eventuality of the carcinogenic risk in humans has been suggested by the results of a few investigations in cell cultures and rodents that showed the genotoxic and carcinogenic potentials of both drugs with no, or only slight, differences between them (18)(19)(20)(21)(22).…”

Section: -Methoxypsoralen: a Reappraisalmentioning

confidence: 99%

A reappraisal of the use of 5‐methoxypsoralen in the therapy of psoriasis

Calzavara‐Pinton

Ortel

Carlino

et al. 1992

Experimental Dermatology

View full text Add to dashboard Cite

5-methoxypsoralen (5-MOP) is considered an alternative to 8-methoxypsoralen (8-MOP) for photochemotherapy of psoriasis. We have compared the clinical efficacy and tolerability of 5-MOP (1.2 mg/kg)-UVA versus 8-MOP (0.6 mg/kg)-UVA therapy in 25 patients of skin type III and IV, affected by relapsing plaque-type psoriasis of similar body involvement; indeed, the same patients were given 8-MOP during 1 year and 5-MOP during the subsequent year after relapsing. Both treatments cleared psoriatic lesions with a comparable number of exposures, but 5-MOP required significantly higher cumulative UVA doses. The difference was due to the lower phototoxicity of 5-MOP, as assessed by the determination of the minimal phototoxic dose, and to its higher tanning activity, as assessed by the weekly grading of pigmentation. Nevertheless, therapy by 5-MOP-UVA seemed particularly interesting in that it showed a higher tolerability since only 1 patient experienced nausea, whereas during therapy with 8-MOP-UVA nausea and/or vomiting occurred in 7 patients, sunburn in 6 and itching in 3. Since we have treated the same patients with the two drugs, our results were not influenced by interindividual variations of phototoxic responses, tanning ability and susceptibility to develop psoralen-induced short-term side-effects. It was concluded that, although long-term side-effects of the 5-MOP-UVA treatment have still to be determined, such treatment of psoriasis should be reappraised due to its higher tolerability in comparison to 8-MOP-UVA treatment.

show abstract

Incidence of skin cancer in Japanese psoriatic patients treated with either methoxsalen phototherapy, Goeckerman regimen, or both therapies

Cited by 46 publications

References 13 publications

Carcinogenic risks of Psoralen UV‐A therapy and Narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review

Carcinogenic risks of Psoralen UV‐A therapy and Narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review

Current Consensus and Update on Psoriasis Therapy: A Perspective from the U.S.

A reappraisal of the use of 5‐methoxypsoralen in the therapy of psoriasis

Contact Info

Product

Resources

About